BHST - BioHarvest Sciences, Inc. Net earnings per share (EPS TTM)
BioHarvest Sciences (BHST) holds patents for hydroponic extraction, creating an insurmountable barrier for competitors. The use of bioreactors ensures seamless scaling and high margins without land costs, while the company actively expands the application of its technologies from nutraceuticals to medicine. The annual earnings per share trend reflects the current trajectory, where the -0.53 mark serves as a key metric.
BioHarvest - analytical breakdowns and key metrics (BHST)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital BioHarvest Sciences|BHST - Long-Term Debt to Equity|Short-Term Debt to Capital bioharvest.com|BHST - Company Total Debt Obligations|Debt to Book Capitalization Ratio BioHarvest Sciences Inc.|BHST - Long-Term Debt|Company Short-Term Debts BioHarvest Sciences|Quick Ratio bioharvest.com
- net income and valuation multiples indicators:
BHST - Net Profit|Expected Profit BioHarvest Sciences|BHST - Company Value to Net Income|Projected Price to Earnings BioHarvest|BHST - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioHarvest Sciences Inc.|BHST - Profit before interest, taxes and amortization|Earnings per share for the last twelve months BioHarvest Sciences|BHST - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months bioharvest.com|BHST - Net earnings per one share growth for the current year|Expected earnings per share growth for next year BioHarvest Sciences
- revenue and sales proceeds data:
Fundamental company analysis:BHST - BioHarvest Sciences Inc
Management ambitions at BioHarvest Sciences (BHST) to scale its botanical synthesis platform require strict validation through operational efficiency. An analysis of the current trailing twelve-month net income per share, reflecting the ratio of bottom-line earnings to the number of securities, allows for an assessment of the business's real yield per share and determines the level of debt burden during the recovery of cash flows, which is critical for evaluating the asset's reliability.
Main competitors
Haleon - Net earnings per share (EPS TTM)|Kenvue - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Corp - Earnings per share for the trailing year|LGND (Ligand Pharmaceuticals Incorporated) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months amneal.com AMRX|Earnings per share for the last twelve months Perrigo (PRGO)|ALVO (Alvotech SA) - Earnings per share for the trailing year|Earnings per share for the last twelve months Liquidia Technologies LQDA|Net earnings per share for the trailing year Galapagos Genomics|ANIP - Earnings per share for the last twelve months|MNKD - Net earnings per share (EPS TTM)|Amphastar Pharmaceuticals (AMPH) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Pacira BioSciences, Inc.|Net earnings per share for the last 12 months SPRY|TBPH: Earnings per share for the trailing year|Earnings per share for the last twelve months aquestive.com (AQST)|Net earnings per share (EPS TTM) scPharmaceuticals, Inc. (SCPH)|Earnings per share for the last twelve months tectonictx.com TECX|Earnings per share for the trailing year TNXP|SXTC - Earnings per share for the last twelve months|Net earnings per share for the last four quarters eupraxiapharma.com EPRX|invizyne.com (EXOZ) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months ORMP (Oramed)|ENTX (Entera Bio) - Net earnings per share (EPS TTM)|HYFT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ABVC|Cumberland Pharmaceuticals - Earnings per share for the last 12 months|Earnings per share for the last twelve months Quantum BioPharma Ltd. QNTM|FGEN: Earnings per share for the last 12 months|TELO - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Rani Therapeutics Holdings|SNYR: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months RLYB (Rallybio Corp.)|LEXX (Lexaria Bioscience Corp.) - Net earnings per share (EPS TTM)|pulmatrix.com (PULM) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pheton (PTHL)|Net earnings per share for the last four quarters Aptorum Group Ltd|Net earnings per share (EPS TTM) LYRA (Lyra Therapeutics Inc)|Impact BioMedical - Earnings per share for the last twelve months|TNF Pharmaceuticals - Net earnings per share (EPS TTM)|YCBD - Net earnings per share (EPS TTM)|PRFX: Net earnings per share (EPS TTM)|CYTO: Earnings per share for the last four quarters|LIPO (Lipella Pharma) - Net earnings per share (EPS TTM)|OPTN: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PIRS|PROC (procapsgroup.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Petros Pharmaceuticals, Inc. PTPI|Qilian International Holding - Earnings per share for the last twelve months|SLRN - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TFFP
